Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 3, Pages e92248
Publisher
Public Library of Science (PLoS)
Online
2014-03-18
DOI
10.1371/journal.pone.0092248
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 3D pancreatic carcinoma spheroids induce a matrix-rich, chemoresistant phenotype offering a better model for drug testing
- (2013) Paola Longati et al. BMC CANCER
- Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
- (2013) D Gonzalez de Castro et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Chemokine receptor expression on integrin-mediated stellate projections of prostate cancer cells in 3D culture
- (2013) Debra L. Kiss et al. CYTOKINE
- Cell migration or cytokinesis and proliferation? – Revisiting the “go or grow” hypothesis in cancer cells in vitro
- (2013) Tamás Garay et al. EXPERIMENTAL CELL RESEARCH
- Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines
- (2013) Anna C. Luca et al. PLoS One
- Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2
- (2013) M. Acunzo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting the Epidermal Growth Factor Receptor in Solid Tumor Malignancies
- (2012) Mette K. Nedergaard et al. BIODRUGS
- Development, validation and pilot screening of an in vitro multi-cellular three-dimensional cancer spheroid assay for anti-cancer drug testing
- (2012) Rati Lama et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation
- (2012) Maria Vinci et al. BMC BIOLOGY
- Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity
- (2012) Miyako Takata et al. CANCER BIOLOGY & THERAPY
- Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
- (2012) T. Yamada et al. CLINICAL CANCER RESEARCH
- Three-dimensional cell culture: the missing link in drug discovery
- (2012) Susan Breslin et al. DRUG DISCOVERY TODAY
- In vivo biomarker expression patterns are preserved in 3D cultures of Prostate Cancer
- (2012) Louisa C.E. Windus et al. EXPERIMENTAL CELL RESEARCH
- OrganDots – an organotypic 3D tissue culture platform for drug development
- (2012) Lars Sundstrom et al. Expert Opinion on Drug Discovery
- Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
- (2012) T. Nakagawa et al. MOLECULAR CANCER THERAPEUTICS
- Rapid Generation of In Vitro Multicellular Spheroids for the Study of Monoclonal Antibody Therapy
- (2012) Yen T. Phung et al. Journal of Cancer
- Differential roles of trans-phosphorylated EGFR, HER2, HER3 and RET as heterodimerisation partners of MET in lung cancer with MET amplification
- (2011) J Tanizaki et al. BRITISH JOURNAL OF CANCER
- Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
- (2011) M Miyamoto et al. BRITISH JOURNAL OF CANCER
- Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
- (2011) Paul Workman et al. CANCER CELL
- Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells
- (2011) H. Xu et al. CLINICAL CANCER RESEARCH
- Role of MetMAb (OA-5D5) in c-MET active lung malignancies
- (2011) Mosmi Surati et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2011) David R. Spigel et al. JOURNAL OF CLINICAL ONCOLOGY
- Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort
- (2011) Seiji Yano et al. Journal of Thoracic Oncology
- Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer
- (2011) Tadaaki Yamada et al. Journal of Thoracic Oncology
- Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma
- (2011) Hidetaka Uramoto et al. LUNG CANCER
- Layer-by-Layer Tissue Microfabrication Supports Cell Proliferation In Vitro and In Vivo
- (2011) Sylvain Catros et al. TISSUE ENGINEERING PART C-METHODS
- High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array
- (2010) Yi-Chung Tung et al. ANALYST
- Incorporation of multicellular spheroids into 3-D polymeric scaffolds provides an improved tumor model for screening anticancer drugs
- (2010) Won Jin Ho et al. CANCER SCIENCE
- Multicellular tumor spheroids: An underestimated tool is catching up again
- (2010) Franziska Hirschhaeuser et al. JOURNAL OF BIOTECHNOLOGY
- Anticancer drug development: the grand challenges
- (2010) William N. Hait NATURE REVIEWS DRUG DISCOVERY
- Anti-tumor activity of noble indirubin derivatives in human solid tumor models In Vitro
- (2009) Soo-Hyun Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
- (2009) M. L. Sos et al. CANCER RESEARCH
- Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer
- (2009) T. Yamada et al. CLINICAL CANCER RESEARCH
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- Mechanisms of collective cell migration at a glance
- (2009) O. Ilina et al. JOURNAL OF CELL SCIENCE
- Three-Dimensional Overlay Culture Models of Human Breast Cancer Reveal a Critical Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibitors
- (2009) Q. Li et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Spheroid-based drug screen: considerations and practical approach
- (2009) Juergen Friedrich et al. Nature Protocols
- Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
- (2008) P. A. Zucali et al. ANNALS OF ONCOLOGY
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
- (2008) Z Tang et al. BRITISH JOURNAL OF CANCER
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor-Activating Mutations
- (2008) S. Yano et al. CANCER RESEARCH
- The State of Innovation in Drug Development
- (2008) I Kola CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modelling tissues in 3D: the next future of pharmaco-toxicology and food research?
- (2008) Giovanna Mazzoleni et al. Genes and Nutrition
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- Network pharmacology: the next paradigm in drug discovery
- (2008) Andrew L Hopkins Nature Chemical Biology
- Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
- (2008) M Pickl et al. ONCOGENE
- Hyaluronan hydrogel: An appropriate three-dimensional model for evaluation of anticancer drug sensitivity
- (2007) Laurent David et al. Acta Biomaterialia
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started